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  INTRODUCTION 
  Conventional dendritic cells (DCs) represent a heterogeneous 
group of antigen-presenting cells located throughout lymphoid 
and extralymphoid tissues of the body that together play a fun-
damental role in the initiation and diversification of adaptive 
immune responses. Although lymphoid-resident DC subsets 
have been the subject of intensive investigation and display 
distinct functional properties,  1 – 3   the functional specialization 
of peripheral tissue-derived migratory DC subsets is less well 
defined. Recent studies by us, and others, have identified a major 
subset of migratory DCs in the intestine, lung, and dermis that 
expresses the     E integrin chain CD103.  4 – 11  
  Several functions have been ascribed to peripheral tissue 
CD103      +       DCs including a role in cross-presenting viral and self-
antigens in lung and skin-draining LNs,  8,12 – 14  cross-presenting 
innocuous inhaled antigen in bronchial LNs,  15   and initiating 
CD4      +       and CD8      +       T-cell responses to soluble intestinal antigens 
in mesenteric LNs (MLNs).  5,16  In addition, murine and human 
small intestinal lamina propria (SI-LP) and MLN CD103      +       DCs 
display an enhanced ability to induce the gut-homing receptors 
CCR9 and    4    7  on responding T cells and promote naive CD4      +       
T-cell differentiation to regulatory T cells (Tregs)  in vitro . 4,5,17 – 20  
Nevertheless, many of these studies have relied on assessing 
the function of CD103      +        DCs   ex vivo,   and the   in vivo   antigen-
presenting capacity of these cells remains unclear. 
 In this study we demonstrate that the CD103 antibody M290 
can be utilized to selectively target antigen to murine CD103      +       
DCs and utilize this strategy to assess the functional capacity of 
this major peripheral tissue migratory DC subset   in vivo .   
  RESULTS   
  M290 is internalized by CD103        +         MLN DCs and associates 
with early and late endosomes 
  The rat IgG2a CD103 antibody M290 is a nondepleting anti-
body,  21  and  in vivo  administration of M290 coupled to the toxin 
saporin (M290-SAP) leads to the selective depletion of CD103      +       
cells including CD103-expressing CD8      +        T cells, DCs, and 
Tregs.  21   To assess whether CD103 could be utilized as a target 
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to deliver antigen to CD103      +        DCs, MLN DCs from wild-type 
and CD103      −      /      −       mice were incubated with M290 or isotype con-
trol (GLIII  /  10) antibody. As expected, M290 but not GLIII  /  10 
bound a subset of MLN DCs from wild-type but not CD103      −      /      −       
mice ( Supplementary Figure S1a  online). Similar to antibodies 
targeting the C-type lectins CD205 and mDCIR1,  22,23  following 
30   min of incubation at 37    ° C, M290 was taken up by MLN DCs 
and colocalized with early endosome antigen-1 (EEA-1)      +       early 
endosomes (  Figure 1a   and   Supplementary Video S1   online, 
data not shown), and at 60     min was occasionally observed to 
be associated with lysosomal-associated membrane protein-1 
(LAMP-1)      +        late  endosomes / lysosomes  ( Figure 1b   and 
  Supplementary Video S2  online). Low cell viability after  in vitro  
culture precluded assessment at later time points. Colocalization 
of M290 with EEA-1      +        or LAMP-1      +        vesicles was not observed 
when MLN DCs were maintained on ice (data not shown). 
  To confirm that M290 targets CD103      +        DCs   in vivo,   fluores-
cently labeled M290 or GLIII / 10 were injected intraperitoneally 
(IP) into C57BL  /  6 mice. After 17     h, animals were killed and 
tissues were analyzed by flow cytometry ( Supplementary Figure 
S1b   online). M290 was detected on CD11c      +      MHCII     +        cells  in 
MLN and SI-LP but less in the spleen, consistent with previ-
ous observations that CD103      +        DCs are rare in the spleen.  4,5  
A similar proportion of CD103      +        DCs was observed in unin-
jected mice after staining for CD103   in vitro   (data not shown), 
demonstrating efficient  in vivo  targeting of DCs in these tissues. 
Analysis of MLN tissue sections demonstrated colocalization of 
M290 with CD11c      +        cells (  Supplementary Figure S1c   online). 
M290 also bound to CD8      +        cells, consistent with expression of 
CD103 on naive and gut-resident CD8      +        T  cells, 24,25   but  not 
B220      +        cells (  Supplementary Figure S1b   online).  Together, 
these results demonstrate that M290 is internalized by CD103      +       
DCs and can be used to target CD103      +        DCs   in vivo .   
  M290.OVA conjugates induce OT-I cell proliferation   in vitro   
and   ex vivo   
  To assess the   in vivo   antigen-presenting capacity of CD103      +       
DCs, M290 and GLIII / 10 were chemically coupled to the model 
Time (min): 0 60 30
60
EEA-1 M290 LAMP-1
EEA-1 M290
Anti-rat
IgG2a
%
 
O
f
 
M
a
x
M290
MHCII+CD11c+
Time (min):
0
20
40
60
80
100
M290.
OVA
GLIII/10.
OVA
DC DC non-
DC
non-
DC
P
e
r
c
e
n
t
 
p
r
o
l
i
f
e
r
a
t
i
o
n
CD103+ cells
CD103– cells
***
***
              Figure 1                          In vivo   M290.OVA-targeted CD103        +         dendritic cells (DCs) induce OT-1 proliferation   ex vivo  . (  a  ,   b  ) Magnetic-activated cell sorting (MACS)-
purified CD11c        +         mesenteric lymph node (MLN) cells were incubated with M290 or GLIII  /  10, washed, and incubated at 37      °  C for the indicated time. 
Cells were then fixed, permeabilized, and costained for (  a  ) the early endosomal marker EEA-1 (early endosome antigen-1) or (  b  ) EEA-1 and the late 
endosomal  /  lysosomal marker, lysosomal-associated membrane protein-1 (LAMP-1). Results are representative cells from one experiment of three 
performed. (  c  ) C57BL  /  6 mice were injected intraperitoneally (IP) with M290.OVA (10        g, clear, solid line) or GLIII  /  10.OVA (10        g, filled). Mice were killed 
after 17    h, and MLN cells were stained with PE-M290 (upper panel) or anti-rat IgG2a (lower panel). Plots are gated on MHCII        +        CD11c        +         cells. Untreated 
mice (clear, dotted line). Results from one representative experiment of three performed is shown. (  d  ) C57BL  /  6 mice were injected IP with M290.OVA 
(10        g) or GLIII  /  10.OVA (20        g). At 17    h after immunization, CD103        +         and CD103        −         MHCII        +         CD11c        +         DCs and CD103        +         and CD103        −         non-DCs were 
sorted from the MLNs and their ability to induce OT-I proliferation assessed by thymidine incorporation. Proliferation is presented as the percentage of 
[  3  H]-thymidine incorporation observed in T cells cultured with CD103        +         DCs from M290.OVA-treated mice (mean c.p.m. 5,045) and is presented in this 
way to normalize between individual experiments. Results are the mean of 3  –  5 independent experiments using pooled cells from 7 mice per condition 
and experiment.   *    *    *    P        <      0.001.   152  VOLUME 5 NUMBER 2 | MARCH 2012 | www.nature.com/mi
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antigen ovalbumin (OVA) ( Supplementary Figure S2a  online). 
At the concentrations tested, M290.OVA- but not GLIII  /  10.
OVA-pulsed MLN DCs induced dose-dependent OT-I prolif-
eration   in vitro   ( Supplementary Figure S2b   online).  This  was 
because of specific targeting and presentation by CD103      +       DCs 
as M290.OVA-pulsed CD103      −       MLN DCs failed to induce OT-I 
proliferation (  Supplementary Figure S2c   online). 
 To determine whether M290.OVA efficiently targets CD103      +       
DCs  in vivo , mice were injected with antibody / OVA conjugates 
IP and animals were killed 17     h later (  Figure 1c  ). MLN DCs 
from mice injected with M290.OVA stained with anti-rat sec-
ondary antibody but failed to bind directly conjugated M290. In 
contrast, MLN DCs from mice that had received GLIII / 10.OVA 
stained with fluorescently labeled M290 but not with anti-rat 
secondary antibody ( Figure 1c ). Thus, CD103-expressing DCs 
were selectively and efficiently targeted by M290.OVA, whereas 
GLIII  /  10.OVA failed to bind DCs   in vivo . 
  To assess whether DCs from mice receiving antibody con-
jugates   in vivo   induced  OT-I  priming   ex vivo ,  antibody / OVA 
complexes were injected IP and 17   h later CD103      +       and CD103      −       
DCs and non-DCs were sorted from the MLNs and co-cultured 
with OT-I cells ( Figure 1d ). Only CD103     +       MLN DCs from ani-
mals receiving M290.OVA induced efficient OT-I proliferation, 
whereas cells from mice receiving GLIII  /  10.OVA induced very 
weak or no proliferation. Collectively, these results demonstrate 
that the M290.OVA conjugates target CD103      +       DCs  in vivo  and 
that these cells can process such conjugates for induction of 
CD8      +        T-cell  responses.   
  Systemic administration of M290.OVA induces OT-I and OT-II 
proliferation   in vivo   
 To determine whether M290.OVA could induce T-cell responses 
  in vivo  , carboxyfluorescein succinimidyl ester (CFSE)-labeled 
OT-I.CD45.1 and OT-II.CD45.1 cells were transferred into 
C57BL  /  6 mice and recipient animals were injected with 
antibody  /  OVA conjugates together with lipopolysaccharide 
(LPS) 1 day later. The amount of each antibody conjugate uti-
lized for injection was normalized to the levels of OVA bound to 
each antibody as determined by enzyme-linked immunosorbent 
assay and are depicted in the figure legends. After 3 days, MLNs 
were isolated from recipient animals and OT-I and OT-II prolif-
eration assessed by flow cytometry. M290.OVA but not GLIII / 10.
OVA and LPS induced both OT-I and OT-II proliferation  in vivo  
(  Figure 2a,b ). This response was dependent on specific targeting 
of the conjugate to CD103      +       antigen-presenting cells as OT-I and 
OT-II cells failed to proliferate in CD103      −      /      −       mice ( Figure 2c,d ). 
The lack of proliferation in CD103      −      /      −       mice was not because of 
a general priming defect in these animals as administration of 
OVA (0.5   mg) IP induced similar T-cell responses in CD103      −      /      −       
and wild-type mice ( Supplementary Figure S3a and b  online). 
Importantly, OT-I and OT-II cells did not proliferate in mice 
injected with OVA (1         g) given together with unconjugated 
M290 and LPS, demonstrating a requirement for selective target-
ing of OVA to CD103      +       cells ( Supplementary Figure S4a and b  
online). Finally, to confirm a role for CD103      +        DCs in T-cell 
priming, diphtheria toxin (DTx)-treated or untreated CD11c.
DTR mice were injected with CFSE-labeled OT-I  /  OT-II cells 
and M290.OVA and LPS. M290.OVA and LPS induced OT-I 
and OT-II proliferation in the MLNs and mediastinal LNs in 
untreated but not DTx-treated CD11c.DTR mice. Efficient 
T-cell priming was also observed in the spleen of untreated but 
not DTx-treated mice, indicating that the few CD103      +        DCs 
present in the spleen also function   in vivo   as efficient antigen-
presenting cells (  Supplementary Figure S5   online).  Together, 
these results provide strong evidence that CD103      +       DCs induce 
both CD8      +        and CD4      +        T-cell responses   in vivo .   
  Systemic administration of M290.OVA generates gut-homing 
T cells   in vivo   but fails to induce efficient FoxP3        +         Treg 
differentiation 
  SI-LP and MLN CD103      +        DCs display an enhanced ability to 
induce the gut-homing receptors CCR9 and    4    7  on responding 
T cells   in vitro . 4,5,16,17,26   To assess the ability of CD103      +        MLN 
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      Figure 2                        M290.OVA induces OT-I and OT-II T cell proliferation   in vivo  . 
(  a    –    d  ) C57BL  /  6 or (  c  ,   d  ) CD103        −        /        −         mice were injected intravenously (IV) 
with carboxyfluorescein succinimidyl ester (CFSE)-labeled CD45.1        +         
OT-I and OT-II cells. PBS, phosphate-buffered saline. After 24    h, mice 
were immunized intraperitoneally (IP) with (  a    –    d  ) M290.OVA (1        g) 
and lipopolysaccharide (LPS; 50        g) or (  a  ,   b  ) GLIII  /  10.OVA (2        g) and 
LPS (50        g). At 3 days after immunization, mesenteric lymph nodes 
(MLNs) were collected and the proliferation (  a  ,   c  ) and cell number 
(  b  ,   d  ) of OT-I  /  OT-II cells assessed by flow cytometry. (  a  ,   c  ) Representative 
flow cytometry plots from mice receiving (  a  ) M290.OVA (clear) or 
GLIII  /  10.OVA (shaded) or (  c  ) M290.OVA in wild-type (wt) mice (clear) or 
CD103        −        /        −         mice (shaded). (  b  ,   d  ) Mean (s.e.m.) from one representative 
experiment of three performed with (  b  ) 4 and (  d  ) 3 mice per group. 
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DCs to induce gut-homing receptors on T cells  in vivo,  OT-I and 
OT-II cell recipients were injected IP with M290.OVA and LPS. 
After 3 days, the majority of MLN-primed OT-I cells expressed 
CCR9 and    4    7  ( Figure 3a ) and OT-I cells readily migrated to the 
small intestinal epithelium ( Figure 3b ). Although OT-II cells were 
also induced to express     4    7  , CCR9 expression was restricted 
to cells that had undergone few divisions and was then lost 
(  Figure 3c  ). Similar expression of gut-homing receptors was 
observed when M290.OVA was injected alone, or when mice 
were injected with FTY720 1 day after immunization to prevent 
effector T-cell egress (data not shown). Together, these results sug-
gest that CD103      +        MLN DCs are more efficient at inducing gut-
homing receptors on CD8      +       T cells than CD4      +       T cells  in vivo . 
  Recent studies have suggested that MLNs are a preferential 
site of peripheral FoxP3 (forkhead box P3)      +        Treg conversion, 
although the observed proportion of converted cells generally 
appears low.  16,17   Given the enhanced ability of SI-LP and 
MLN CD103      +        DCs to promote induced Treg differentiation   
in vitro , 16,17  we hypothesized that selective antigen presentation 
by CD103      +       MLN DCs  in vivo  may dramatically enhance induced 
Treg conversion in the MLNs. To assess this, recipients of naive 
OT-II cells were immunized with M290.OVA with / without LPS 
IP, and FoxP3      +       expression in responding cells was determined 3 
days later. Under these conditions, 3 – 6 %  of OT-II cells expressed 
Foxp3      +        ( Figure 3d  ). Similar percentages of FoxP3      +        Tregs were 
observed in mice that were injected with FTY720 at 1 day after 
immunization, to prevent lymphocyte egress ( Figure 3e ). Notably, 
a similar degree of FoxP3      +        Treg generation was observed after 
oral OVA administration (  Figure 3e  ), a process that requires 
DC-mediated antigen transport to draining MLNs.  27,28    
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              Figure 3                        CD103        +         mesenteric lymph node (MLN) dendritic cells (DCs) generate gut-homing T cells   in vivo   but are poor at inducing FoxP3 (forkhead 
box P3)        +         regulatory T cell (Treg) differentiation. (  a  ) Representative flow cytometry plots of gut-homing receptor expression on OT-I cells in the MLNs 
3 days after immunization with M290.OVA (1        g) and lipopolysaccharide (LPS; 50        g). Numbers are mean (s.e.m.) positive cells among dividing cells 
from 10 mice in 4 separate experiments. CFSE, carboxyfluorescein succinimidyl ester. (  b  ) C57BL  /  6 or CD103        −        /        −         mice were immunized with M290.
OVA (1        g) or GLIII  /  10.OVA (2        g) with LPS and their migration to the small intestinal epithelium determined by flow cytometry. Results are the mean 
(s.e.m.) from one representative experiment of four, with three mice per group. IEL, intraepithelial lymphocyte; PBS, phosphate-buffered saline; wt, 
wild type. (  c  ) Representative FACS plots of gut-homing receptor expression on OT-II cells in the MLNs 3 days after immunization with M290.OVA 
(1        g) and LPS. Numbers are the mean (s.e.m.) positive cells among dividing cells from 12 mice in 4 separate experiments. (  d  ,   e  ) Representative 
flow cytometry plots of FoxP3 expression on OT-II cells in the MLNs 3 days after intraperitoneal (IP) immunization with (  d  ) M290.OVA (1        g) and LPS 
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  Systemic administration of M290.OVA induces tolerance or 
immunity depending on the instruction of DC maturation 
 We next addressed the ability of M290.OVA to induce functional 
effector immune responses. Previous studies have proposed that 
adequate induction of CD8      +        effector T-cell responses by DCs 
(the   “  license to kill  ”   theory) can be instructed by CD4 helper 
T cells that provide a maturation stimulus to DCs via CD40L 
acting on CD40, a system that can be replaced by systemic injec-
tion of CD40 agonistic antibodies.  29 – 31  Therefore, recipients of 
OT-I cells were immunized IP with antibody  /  OVA conjugates 
with or without agonistic CD40 antibody. After 3 days, MLN 
cells from recipient mice were stimulated with phorbyl myri-
state acetate and ionomycin for 4     h, and interferon-     (IFN-  ) 
production by OT-I cells was assessed by flow cytometry. 
IFN-    -producing OT-I cells were abundant in MLNs of mice 
immunized with M290.OVA plus   CD40, but not in mice given 
M290.OVA alone or GLIII / 10.OVA plus   CD40 ( Figure 4a ). To 
determine whether this immunization regime led to the genera-
tion of cytotoxic CD8      +        T cells,  32   C57BL / 6  or  CD103     −      /      −        mice 
were injected IP with antibody / OVA complexes with or without 
    CD40, and killing of adoptively transferred OVA-pulsed tar-
get cells was assessed in the spleen 12 days later (  Figure 4b,c ). 
Immunization with M290.OVA plus   CD40, but not M290.OVA 
alone  or  GLIII / 10.OVA  plus     CD40, induced the generation 
of cytotoxic T lymphocytes (CTLs). Again, this response was 
dependent on targeting to CD103      +       cells, as it was not observed 
in CD103      −      /      −        mice (  Figure 4b,c ). 
 Coadministration of LPS or   CD40 / polyinosinic:polycytidylic 
acid (poly I:C) together with antibody / OVA targeting complexes 
has previously been shown to induce antigen-specific antibody 
responses   in vivo . 33   To assess whether coadministration of 
these adjuvants with M290.OVA could induce antigen-specific 
antibody responses, C57BL  /  6 mice were injected with M290.
OVA alone or together with     CD40  /  poly I:C or LPS. After 4 
weeks, mice were boosted by IP injection of OVA and 6 days 
later serum levels of OVA-specific antibodies were determined 
by enzyme-linked immunosorbent assay. Coinjection of LPS 
with M290.OVA led to the generation of OVA-specific IgG1 
and IgG2a, whereas administration of M290.OVA or adju-
vant alone gave no response (  Figure 4d  ). These results were 
confirmed using    CD40 / poly  I:C  as  combined  adjuvants 
(  Figure 4d ). Together, these results suggest that CD103      +       DCs in 
the presence of appropriate stimuli can prime immunity. 
  The absence of CTL or IFN-     expression  in  CD8     +        T cells in 
mice receiving M290.OVA alone, despite induction of CD8      +       
T-cell division, indicated that injection of M290.OVA to tar-
get CD103      +        DCs in the steady state may induce tolerance in 
responding CD8      +        T cells. To address this, recipients of OT-I 
cells were injected IP with M290.OVA with or without    CD40 
or with phosphate-buffered saline (PBS) alone. After 12 days, 
mice received OVA in Complete Freund  ’  s Adjuvant (CFA) IP 
and 3 days later mice received an equal ratio of OVA peptide-
pulsed (CFSE  lo ) and unpulsed (CFSE  hi ) splenocyte targets. OVA 
peptide-pulsed splenocytes were selectively lysed in the MLNs 
and spleen of mice receiving PBS, or antibody / OVA conjugates 
together with   CD40 ( Figure 5a,b ), reflecting the induction of 
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            Figure 4                        CD103        +         dendritic cells (DCs) generate antigen-specific 
cytotoxic T lymphocytes (CTLs) and antibody responses in the presence 
of adjuvant. (  a  ) M290.OVA plus     CD40 alone induces interferon-     (IFN-    ) 
production in responding OT-I cells. Recipients of OT-I cells were injected 
intraperitoneally (IP) with M290.OVA (5        g) or GLIII  /  10.OVA (15        g) 
with  /  without     CD40. At 3 days after immunization, mesenteric lymph node 
(MLN) cells were isolated and restimulated with phorbyl myristate acetate 
(PMA) and ionomycin and intracellular expression of IFN-     in OT-I cells was 
determined by flow cytometry. Mean (s.e.m.) of 5  –  6 mice per group from 
two separate experiments. (  b  ,   c  ) M290.OVA plus     CD40 induces antigen-
specific CTL. M290.OVA (10        g) or GLIII  /  10.OVA (20        g) with  /  without     CD40 
were injected IP into wild-type (WT) or CD103        −        /        −         mice. After 12 days, 
animals received peptide-pulsed (CFSE  lo  ) and unpulsed (CFSE  hi  ) target 
cells and CTL activity was assessed in the spleen the following day by flow 
cytometry. (  b  ) Representative flow cytometry plots and (  c  ) mean (s.e.m.) 
of 5  –  9 mice per group from three experiments.   *    *    *    P        <      0.001. (  d  ) M290.OVA 
and adjuvant induces ovalbumin (OVA)-specific antibody responses. Mice 
were immunized IP with M290.OVA (filled symbols) alone (2.5        g, square) 
or together with lipopolysaccharide (LPS; 50        g, triangle) or polyinosinic:
polycytidylic acid (polyI:C; 50        g)  /      CD40 (50        g) (diamond). Control mice 
received only LPS (clear triangle) or polyI:C  /      CD40 (clear diamond). 
After 4 weeks, mice received an IP injection with OVA (5        g) and 6 days 
later serum levels of OVA-specific IgG1 and IgG2a was determined by 
enzyme-linked immunosorbent assay (ELISA). Data are the mean (s.e.m.) 
from one representative experiment of three (M290.OVA and LPS) or one 
(M290.OVA and polyI:C  /      CD40) performed with three mice per group per 
experiment. Immunization with M290.OVA and LPS and M290.OVA and 
polyI:C  /      CD40 induced significant IgG1 and IgG2a responses compared 
with M290.OVA alone (  P        <      0.0001) as determined by two-way analysis of 
variance (ANOVA) test.   MucosalImmunology | VOLUME 5 NUMBER 2 | MARCH 2012   155
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antigen-specific CD8      +        CTL effectors by the OVA  /  CFA immu-
nization. In sharp contrast, peptide-pulsed splenocyte targets in 
mice receiving only M290.OVA remained largely viable, despite 
immunization  with  CFA / OVA  ( Figure 5a,b  ). Thus, CD103      +       
DCs induce CTL tolerance in the absence of surrogate T-cell 
contact.   
  Mucosal intratracheal delivery of M290.OVA induces T-cell 
proliferation in draining mediastinal LNs and tolerance to 
inhaled antigen 
  The above data suggested that antigen presentation by CD103      +       
DCs in the steady state leads to tolerance or immunity in the 
CD8      +       T-cell compartment. However, all experiments were per-
formed using systemic IP injection of M290.OVA, potentially 
also targeting DCs that are already resident in the LNs or spleen 
at the time of injection. To address the function of peripheral 
CD103      +       DCs, we focused our attention to the lung, as antibod-
ies can be injected into the trachea without the risk of being 
degraded and without mechanical breaching of physiological 
barriers. In the lung, CD103      +        DCs are closely associated with 
pulmonary epithelial cells, extending their dendrites into the 
airway lumen and represent a major population of migratory 
DCs.  6,8,11  To assess whether mucosal application of M290.OVA 
could be utilized to target tissue-resident CD103      +        DCs,  recipi-
ents of OT-I and OT-II cells received antibody / OVA conjugates 
by intratracheal (IT) injection ( Figure 6a ). Administration of as 
little as 28     ng of M290.OVA was sufficient to induce both OT-I 
and OT-II proliferation in draining mediastinal LNs ( Figure 6a  
and  Supplementary Figure S6a  online), demonstrating remark-
able targeting efficiency of this reagent across the lung mucosa. 
 We next utilized this system to study the functional outcome 
of mucosal application of M290.OVA, focusing specifically on 
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mucosal tolerance. To address induction of inhalation tolerance, 
mice received antibody / OVA complexes IT, and 7 days later were 
immunized IP with OVA and the T helper type 2 (Th2) adjuvant 
alum. After 10 days, mice were challenged for 3 consecutive days 
with 1 %  OVA aerosol to elicit allergic type airway inflammation. 
At 24     h after the last challenge, bronchoalveolar lavage (BAL) 
fluid, mediastinal LN, and serum were collected to address the 
induction of asthma features. In mice injected with PBS before 
immunization with OVA / alum and aerosol exposure, there was 
induction of airway eosinophilia (  Figure 6b ),  accompanied  by 
Th2 cytokine production in the mediastinal LN lymphocytes 
(  Figure 6c  ), a rise in serum OVA-specific immunoglobulin E 
(IgE) levels ( Figure 6d ) as well as inflammatory peribronchiolar 
and perivascular infiltrates ( Supplementary Figure S6b  online). 
These features of allergic asthma were severely reduced when 
mice received a single injection of 100     g of OVA intratracheally 
before the immunization protocol, demonstrating the effect of 
inhalation tolerance induction. The IT administration of M290.
OVA but not GLIII  /  10.OVA also significantly attenuated air-
way eosinophilia, mediastinal LN Th2 cytokine production, and 
anti-OVA IgE antibody responses to OVA  /  Alum, to the degree 
observed in mice receiving 100         g of soluble OVA. Therefore, 
targeting OVA specifically to mucosal CD103      +        lung DCs is 
highly efficient in inducing inhalation tolerance.     
  M290 targets distinct and partially overlapping subsets of 
DCs compared with DEC205 and 33D1 antibodies 
  Targeted delivery of antigen to DCs   in vivo   has  therapeutic 
potential in vaccine design and for antitumor and disease-
modulation therapies.  34  Two targets on DCs that have received 
particular attention are the C-type lectin receptors DEC205 and 
DCIR2 (recognized by the monoclonal antibody 33D1) that are 
expressed on splenic CD8      +        and  CD8     −        DCs,  respectively. 2,31,35  
To determine whether the DC subsets targeted by CD103 are 
similar or distinct from those targeted by DEC205 and 33D1, 
expression of DEC205 and 33D1 on CD103      +        and  CD103     −       
MLNs, mediastinal LNs, and splenic DCs was assessed by flow 
cytometry (  Figure 7  ). DEC205 was expressed on the major-
ity of CD103      +        DCs  in  MLNs  (80 % ),  mediastinal  LNs  (85 % ), 
and spleen (83  %  ), as well as on a large proportion of CD103      −       
DCs (  Figure 7a  – c   ). In contrast, 33D1 was expressed on   ~  40  %   
of CD103      +       DCs in MLNs and on only a minor fraction of medi-
astinal LNs (5 % ) and splenic CD103      +       DCs (34 % ), but on a size-
able fraction of CD103      −       DCs in all three tissues ( Figure 7a – c  ). 
Thus, M290 targets a distinct array of DCs compared with 
DEC205  and  33D1.    
  DISCUSSION 
 CD103     +        DCs represent a major subset of migratory DCs in 
peripheral tissues including the lung, intestine, and dermis; 
however, their   in vivo   functional activities remain to be fully 
elucidated. Here, by conjugating OVA to the CD103 antibody, 
M290, we were able to directly address the priming potential of 
CD103      +        DCs   in vivo . 
  Our results show that CD103      +        DCs in MLN, spleen, and 
mediastinal LNs are capable of stimulating both CD4      +        and 
CD8      +        T-cell responses   in vivo  . Administration of M290.OVA 
alone induced antigen-specific tolerance, suggesting that 
CD103      +        DCs promote tolerogenic responses in the steady 
state. However, coadministration of adjuvant switched this 
tolerogenic activity to one of immunity, leading to the gen-
eration of antigen-specific CTLs and antibody responses. 
These results demonstrate that CD103      +        DCs, when appropri-
ately activated, can be induced to promote effector responses   
in vivo  . Although from these   in vivo   studies, we could not 
determine whether CD103      +        DCs residing in different loca-
tions differed in their immune-promoting activities, these 
results are consistent with recent, primarily   in vitro,   observa-
tions that even intestinal CD103      +        DCs when appropriately 
stimulated can switch from a tolerance to immune-promoting 
phenotype.  36 – 38  
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 Consistent with previous  in vitro  findings, 4,16,19  CD103     +       MLN 
DCs efficiently induced gut-homing receptor expression on OT-I 
cells   in vivo  ; however, surprisingly little CCR9 was induced on 
OT-II cells. Although the reason for inefficient CCR9 induction 
on CD4      +        T cells is currently unclear, we consistently observe 
less CCR9 induction on OT-II cells compared with OT-I cells 
following oral or IP administration of OVA (M. Svensson-Frej, 
M. Semmrich, unpublished observation; B. Johansson-Lindbom, 
personal communication), indicating that such differences are not 
due to the M290 targeting strategy. Gut-homing receptor induc-
tion on T cells in the MLN  in vivo  and by CD103      +       DCs  in vitro  
is dependent on the Vitamin A (retinol) metabolite retinoic 
acid.  19,20,39   Thus, one possibility is that CD4      +        T-cell priming   
in vivo  occurs in a less retinoic acid-rich environment. For exam-
ple, different subsets of CD103      +        MLN DCs may preferentially 
prime CD4      +        and CD8      +        T cells   in vivo  , and the CD103      +        DC 
subset that primes CD4      +       T cells may be less efficient at generat-
ing retinoic acid. Alternatively, as subsets of MLN stromal cells 
generate retinoic acid,  40  the MLN stromal environment in which 
CD4      +        and  CD8     +        T-cell priming takes place may also differ. 
A second possibility is that CD4      +       T cells receive additional com-
peting differentiation signals   in vivo  . In this regard, CXCR5      +       
follicular helper OT-II cells develop in parallel to gut-homing 
OT-II cells in the MLNs following IP administration of OVA 
and adjuvant.  41  Finally, antigen dose is an important parameter 
in regulating tissue homing receptor expression at least on OT-
I cells,  19   and thus the amount of antigen presented on major 
histocompatibility complex class I (MHC-I) and MHC-II may 
influence the efficiency of gut-homing receptor induction. 
  In addition to their ability to induce gut-homing recep-
tors, CD103      +        MLN DCs have received considerable attention 
because of their enhanced capacity to promote FoxP3      +        T-cell 
differentiation   in vitro  , a property that appears, at least in part, 
to be mediated through their ability to generate transform-
ing growth factor-     and retinoic acid.  16,17,42,43   We were thus 
initially surprised that   in vivo   targeting of antigen to CD103      +       
DCs did not induce higher OT-II cell conversion to FoxP3      +       
Tregs in the MLNs   in vivo  . Nevertheless, we and others have 
previously demonstrated that CD103      +        DCs play a central role 
in picking up and presenting oral antigen to CD4      +       T cells in the 
MLNs,  5,16   and  under  similar  conditions,  only  1 – 8 %   of  CD4     +       
T cells convert to FoxP3      +        Tregs in the MLNs.  16,17,28   In addi-
tion, in the absence of exogenous transforming growth factor-  , 
FoxP3      +       Treg conversion by CD103      +       DCs  in vitro  also lies within 
this  range  (2.5 – 8 % ). 16,17   Together, these findings suggest that 
CD103      +       DC-mediated FoxP3     +       Treg conversion in MLNs  in vivo  
is rather inefficient and are in line with a recent study suggesting 
that the expansion of newly differentiated FoxP3      +       Tregs occurs 
primarily in the SI-LP.  28  
 The possibility of selectively targeting antigen to mucosal DCs 
by mucosal application of antibody  /  antigen complexes has not 
to our knowledge been previously assessed. Here, we demon-
strate that IT administration of M290.OVA but not GLIII.10.
OVA was extremely efficient at inducing antigen-specific 
CD4      +        and  CD8     +        T-cell proliferation in draining mediastinal 
LNs. The ability of lung-derived CD103      +        DCs to prime CD4      +       
T cells contrasts with a report from del Rio   et al.  15   indicating 
that these cells, while efficiently cross-presenting soluble 
antigen, are poor at priming CD4      +        T cells, although they are 
consistent with the observation that mediastinal LN CD103      +       
DCs from mice infected with OVA-expressing influenza virus 
prime OVA-specific CD4      +        T cells   ex vivo . 8   Notably,  despite 
inducing antigen-specific CD4 and CD8 T-cell proliferation, 
the outcome of IT M290.OVA administration was inhalation 
tolerance as measured by reduced levels of antigen-specific 
IgE, Th2 responses, and eosinophil accumulation in the BAL 
fluid. Although more studies are needed to determine the 
mechanism(s) by which this subset of DCs induce tolerance, 
for diseases like asthma, one can envisage tolerizing protocols 
exploiting the steady-state immunoregulatory potential of 
mucosal CD103      +        DCs to induce more long-lasting prevention 
of disease features. 
  Specific targeting of antigen to DCs   in vivo   with  antibodies 
or ligands has proven a feasible means of enhancing adaptive 
immune responses and has great potential in the field of vac-
cination therapy.  34  Although targeting strategies have tended to 
focus on the C-type lectin receptor family, including DEC205, 
DC-SIGN, Mannose receptor, CLEC9A, and DCIR2,  34,44,45  anti-
body-mediated targeting to CD11c was also recently shown to 
be highly effective in the generation of CD4      +        and CD8      +        T-cell 
responses and antitumor immunity.  46,47  Our demonstration that 
CD103 can function as an uptake receptor on DCs and induce 
antigen-specific CD4      +       and CD8      +       T-cell priming  in vivo  further 
expands the array of potential receptors that may be utilized 
for the targeted delivery of antigen and / or immunomodulatory 
substances to DCs  in vivo . Our results suggest, at least in mouse, 
that CD103 is expressed on a partially overlapping, and partially 
distinct set of DCs compared with DEC205      +        and  33D1     +        DC 
subsets. Although additional studies are required to directly 
compare these targeting strategies in different immunological 
models, we hypothesize, based on the accumulated evidence that 
distinct DC subsets display different functional characteristics, 
that targeting CD103      +       DCs (either via CD103 or other receptors 
on these cells) may prove advantageous in certain settings. In 
this regard, CD103      +       DCs with similar function and phenotype 
have been identified in human MLNs and are also present in 
the intestinal lamina propria and skin-draining LNs.  5,18,48,49  
Furthermore, in contrast to the mouse,  25   the majority of naive 
human CD8      +        T cells do not express CD103.  50    
  METHODS         
  Mice   .   C57BL / 6, OT-I.CD45.1, OT-II, OT-II.CD45.1, C57BL / 6.CD45.1, 
and CD103      −      /      −        mice were bred and maintained at the Biomedical 
Center Animal Facility (Lund University, Lund, Sweden) and used 
between 6 and 14 weeks of age. CD11c.DTR mice were bred and main-
tained at the Experimental Biomedicine Animal Facility, University of 
Gothenburg, Sweden. All animal experiments were approved by the 
Lund / Malm ö  animal ethics committee.   
  Antibodies and reagents   .    The  following  antibodies  and  reagents 
were used during the course of this study: PE-CD103 (M290), PE-    4    7  
(DATK32), PE-CD11c (N418), bio-CD45.1 (A20), APC-CD8   (53 – 6.7), 
PE-V    (MR9-4), bio-V  2 (B20.1), FITC or bio-CD8   (53-5.8), PE or bio-
rat IgG2a (RG7  /  1.30), bio-rat IgG2b (G15-337), and anti-rat IgG-APC 158  VOLUME 5 NUMBER 2 | MARCH 2012 | www.nature.com/mi
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(all from BD Bioscience, Franklin Lakes, NJ); pacific blue-MHC class II 
(M5 / 114.15.2), Alexa700-CD45.1 (A20), Alexa700-CD45.2 (104), CD40 
(1C10), and PE-Cy5-NK1.1 (PK136) (all from BioLegend, San Diego, 
CA); bio-CD103 (2E7), bio- or pacific blue-CD8     (53-6.7),  PE-Cy7-
CD11c (N418), PE or PE-Cy7-B220 (RA3-6B2), PE-Cy7-CD4 (GK1.5), 
pacific blue-CD4 (RM4-5), IFN-    – PE-Cy7  (XMG1.2),  APC-FoxP3 
(FJK16s), Alexa Fluor-647-CD107a (eBio1D4B), PE-Cy7-CD25 (P61.5), 
PE-Cy5-CD3 (145-2C11), PE-Cy5-CD19 (eBio1D3), bio-33D1 (33D1), 
streptavidin-conjugated APC, and the Foxp3 staining kit (all from eBio-
science, San Diego, CA). Anti-EEA-1 (rabbit polyconal) was from Cell 
Signaling Technology (Danvers, MA). Bio-DEC-205 (NLDC-145) was 
from Abcam (Cambridge, UK). Cy3-conjugated donkey anti-rabbit IgG-
F(ab  ’  )2 was from Jackson Immunoresearch Laboratories (West Grove, 
PA). Anti-CCR9 antibody,  51  anti-CD103 (M290), and rat IgG2a isotype-
control (GLIII / 10) were purified from hybridomas. Alexa Fluor-647 pro-
tein-labeling kit was from Invitrogen (Carlsbad, CA). OVA grade VII, 
LPS ( Escherichia coli , serotype 055:B55), DNase I, collagenase type IV and 
VIII, CFA, and CFSE were from Sigma-Aldrich (St Louis, MO). FTY720 
was obtained from Cayman Chemical (Ann Arbor, MI). Synthetic pOVAs 
(OT-I, SIINFEKL and OT-II, ISQAVHAAHAEINEAGR) were from 
Innovagen (Lund, Sweden).    
  Cell isolation   .   Intraepithelial lymphocytes and lamina propria cells were 
isolated as previously described.  25,52  For isolation of LN T cells and DCs, 
LNs were cut and filtered directly through a 70     m cell strainer or incu-
bated with collagenase IV (500        g   ml  – 1 )  and  DNAse  I  (50   U   ml  – 1 )  for 
30   min  at  37    ° C  before  filtering,  respectively.  CD4     +        and  CD8       +        T  cells 
were enriched to     >    85 %  purity by magnetic-activated cell sorting (MACS; 
Miltenyi Biotech, Bergisch Gladbach, Germany) using CD4 MACS beads 
or bio-anti-CD8     (53-5.8) followed by streptavidin-conjugated MACS 
beads, respectively. In  Figure 1a  and  Supplementary Figure S2b and c , 
DCs were isolated from mice injected with Flt3L (FMS-like tyrosine 
kinase-3 ligand)-secreting B16 melanoma cells.    
  Flow cytometry and cell sorting   .    Flow  cytometry  was  performed 
according to standard procedures. Dead cells were identified using 
propidium iodide staining or Live Dead Fixable Violet  /  Red Dead cell 
staining kit (Invitrogen) and removed from the analysis. Data acquisi-
tion was performed on a FACSCalibur, FACS LSRII, or FACSAria (BD 
Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, 
OR). For purification of CD103      +        and CD103      −        DCs, MACS-enriched 
CD11c      +       DCs were stained with anti-CD11c, anti-CD103, and anti-MHC 
class II and sorted on a FACSAria.  4  DC fractions were routinely 95 – 99 %  
pure, respectively.    
  Immunohistochemistry   .    T i s s u e  s e c t i o n s  ( 7      m) were fixed in 4 %  para-
formaldehyde. After blocking with rat and goat serum (10  %   of each in 
PBS, 0.05  %   Tween), sections were incubated with anti-CD11c (N418), 
followed by anti-B220-FITC (RA3-6B2) and Cy3 goat anti-hamster IgG 
(polyclonal, Jackson ImmunoResearch).    
  Antibody uptake assay   .    MLN  DCs  were  isolated  using  CD11c 
microbeads (Miltenyi Biotec) and were 90 %  CD11c      +      MHC class II      +      . DCs 
were labeled with biotinylated M290 or isotype control for 30   min on ice 
followed by labeling with Alexa-488 conjugated streptavidin (Invitrogen) 
for 15   min on ice. The cells were washed in medium and incubated at 37    ° C 
for indicated time periods. For intracellular staining of lysosomes and 
endosomes, DCs were fixed and permeabilized with Leucoperm (AbD 
Serotec, Kidlington, UK) and stained with Alexa-647 conjugated anti-
CD107a (LAMP-1) and rabbit anti-EEA1mAb followed by anti-rabbit 
IgG-Cy3. Cells were centrifuged on coverslips and mounted in ProLong 
Gold anti-fade reagent (Invitrogen) and imaged with an epifluorescent 
microscope (Axiovert 200M; Carl Zeiss AB, Stockholm, Sweden) equipped 
with a  × 63 1.4 Plan-Apochromat oil objective and Hamamatsu Orca-ER 
camera. Images were acquired at 0.3         m steps spanning the entire cell, 
deconvolved by fast restoration, and three-dimensional reconstructions 
prepared using Volocity software 5.2.1 (Perkin Elmer, Waltham, MA).    
  Generation of antibody  /  OVA conjugates   .   M290 and GLIII / 10 were con-
jugated to maleimide-activated OVA (Pierce Biotechnology, Rockford, IL) 
according to the manufacture ’ s protocol. Briefly, antibodies were reduced 
with 2-mercaptoethylamine HCl (MEA) and separated from MEA over 
a desalting column. Maleimide-activated OVA and reduced antibodies 
were incubated in a 1:1 molar ratio for 2   h at room temperature. Samples 
were run over a protein G column (Pierce Biotechnology) to remove 
unbound OVA. Western blot was performed to confirm conjugation and 
removal of unbound OVA and enzyme-linked immunosorbent assay was 
performed according to standard techniques to determine the amount of 
OVA conjugated to each antibody. GLIII / 10.OVA conjugates consistently 
contained less OVA than M290.OVA conjugates (approximately twofold 
less) and the concentrations used for experiments adjusted accordingly.   
    In vitro   proliferation assay   .   DCs were pulsed with antibody / OVA con-
jugate for 3     h, washed extensively, and incubated in a 1:2 ratio with OT-
I cells (2  ×  10  5  ) in 96-well flat-bottom plates (Thermo Fisher Scientific, 
Waltham, MA) in 200        l  R10-medium  (RPMI-1640,  10 %   fetal  calf 
serum, 10   m M  Hepes, 1   m M  sodium pyruvate, 50      M  mercaptoethanol, 
100   U   ml  – 1   penicillin,  100     g   ml  – 1   streptomycin,  and  50     g   ml  – 1   gen-
tamicin; all from Invitrogen). Cell proliferation was determined by add-
ing 1     Ci [ 3 H]-thymidine (Amersham Biosciences, Uppsala, Sweden) to 
the cultures at 24   h and assessing thymidine incorporation 16   h later.    
    In vivo    T-cell priming   .   MACS-purified OT-I.CD45.1 and OT-II.CD45.1 
cells were labeled with CFSE according to standard protocols and injected 
(3 – 5 × 10 6 ) intravenously into C57BL / 6 or CD103     −      /      −       mice. To determine 
the generation of FoxP3      +       CD4     +       T cells, naive CD4      +      CD44 lo CD25     −      FR4     −   
   CD69     −       were sorted from OT-II mice before their transfer into recipient 
animals. For IT immunization, MACS-purified OT-I.CD45.1 or OT-
II.CD45.1 cells were labeled with CFSE according to standard protocols 
and injected (3 – 5 × 10 6 ) intravenously into C57BL / 6. After 24   h, recipients 
were immunized IT with antibody / OVA conjugates at the indicated dose. 
In some experiments, mice received FTY720 (1     mg     kg   – 1   body weight; 
Cayman, Talinn, Estonia) IP 24     h later. For DC depletion, CD11c-DTR 
mice were injected IP with 4   ng   g   – 1  body weight DTx at the time of OT-I 
and OT-II T cell transfer. Recipients were immunized IP with antibody /
 OVA conjugates at the indicated dose.    
    In vivo   cytotoxicity assay   .    Splenocytes  were  incubated  with / without 
SIINFEKL peptide (0.2           M  ) for 2     h at 37       °  C, washed, and labeled with 
low  (0.2      M )  and  high  (2        M  ) doses of CFSE, respectively. After wash-
ing, labeled cells were mixed in a 1:1 ratio and intravenously injected 
into recipient animals (6  ×  10  6   cells per mouse). After 17     h, spleens and 
MLN cell suspensions from the recipients were stained and analyzed by 
flow cytometry. The percentage of killing was quantified as (1       −       (ratio 
unprimed  /  ratio primed))  ×  100, with ratio determined as   %  CFSE non-
pulsed /   % CFSE pulsed cells. For intracellular cytokine analysis, MLN cells 
from recipients of OT-I cells were isolated 3 days after immunization, and 
restimulated with phorbyl myristate acetate (100   ng   ml   – 1 ; Sigma-Aldrich) 
and ionomycin (1        g   ml  – 1  ; Sigma-Aldrich). Brefeldin A (20        g   ml  – 1 ; 
Sigma-Aldrich) was added after 1     h, cells were harvested 4     h later, and 
stained for intracellular IFN-   according to standard techniques.    
    In vivo   tolerance model   .    C57BL / 6  mice  were  immunized  IT  with 
antibody / OVA  conjugates,  OVA wortington   (100      g), or PBS as control. 
After 7 days, mice were injected IP with 500         l of Imject alum suspen-
sion  (1   mg)  containing  10      g of OVA (OVA-alum). After 10 days, mice 
were challenged with 1  %   OVA GIII (Sigma, St Louis, MO) aerosols 
for 3 consecutive days. At 24     h after the last challenge, serum, BAL, and 
mediastinal LNs were obtained. Enzyme-linked immunosorbent assay 
was performed to measure antibody response in serum and cytokine pro-
duction from mediastinal LNs (eBioscience) after restimulation for 3 days 
with OVA (20     g   ml  – 1 ). To determine the cellular composition of BAL flu-
ids, cells were stained with MHCII-FITC (2G9; for DC and macrophage 
staining), CD11c-APC (HL3; for DC staining), CD19-CyChr (RA3-6B2) 
and CD3-CyChr (145-2C11; BD), and Siglec F-PE (R  &  D Systems, MucosalImmunology | VOLUME 5 NUMBER 2 | MARCH 2012   159
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Abingdon, UK; for eosinophil staining). The cellular composition of BAL 
fluid was determined using flow cytometry. For histology sections, lungs 
were inflated using OCT (optimal cutting temperature compound) / PBS 
and frozen. Subsequently, cryosections were made and stained with peri-
odic acid-Schiff reagent (Sigma) and photographed with an Olympus 
BX53 microscope (Olympus, Center Valley, PA).    
  Statistical analysis   .    Unless  otherwise  mentioned,  statistical  analyses 
were performed using unpaired or paired two-tailed Student  ’  s test. 
 *  P     <    0.05;  *  *  P     <     0.01; and  *  *  *  P     <    0.001.        
        SUPPLEMENTARY MATERIAL   is linked to the online version of the 
paper at   http://www.nature.com/mi       
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